Censo Biotechnologies (Axol Bioscience Ltd.)’s Post

Whether you're looking to use iPSCs for the first time or want to scale up your in vitro projects, let us know what we can do to help. This year we're pledging to support the iPSC community, helping researchers to unlock the benefits of iPSC technology for better human disease models. As part of this pledge, we're making it easier and more affordable to access and use market-leading iPSC technology. That includes those new to iPSCs, researchers already engaged with iPSC technology, and groups looking to scale up in size and complexity. Take a look at our 2024 promotions and pricing structures to see how we can support you in your iPSC journey: https://hubs.la/Q02gTSZZ0 Want to discuss a project? Get in touch with us at operations@axolbio.com #iPSCs #StemCells #DrugDiscovery #biotech

Genomic stability monitoring is absolutely critical for iPSC work. Around 20-30% of iPSC lines have a genomic anomaly which can impact the cells’ growth and differentiation properties and is a significant cause of cell line and data reproducibility issues. RESCUE uses the Advanced Instruments, LLC VIPS and CMX instruments to recover cell lines which have acquired unwanted changes. Visit Advanced Instruments at the 4th Annual iPSC Drug Development & Manufacturing Summit on Thursday the 3rd of October 12.30pm EDT to learn more. #ipsc #stemcells #QC #celltherapy #geneediting #celllinedevelopment #cellculture #drugdiscovery

When it comes to iPSCs, in 2024 we're asking one simple question: what can we do to help? We believe in the enormous potential of iPSCs for drug discovery to unlock better, safer therapies for neurodegenerative and cardiovascular diseases. And we're here to support drug discovery researchers who want to harness iPSC technology and realize this potential. We've been working with iPSCs in a quality-focused environment for over a decade and have developed a deep understanding of the challenges of this space. So whether it's compound screening on physiologically useful models, iPSC creation, QC and banking, or the large-scale supply of functionally-relevant cells, we can help you. Our capabilities include: • High-quality, functionally consistent axoCells™ • A bank of over 70 fully characterized and licensed axoLines™ • Our QC-rich axoServices™ • The ability to work with you to build, validate and use iPSC-based axoModels™. Collaboration is one of our six core company values; we're here to help you by doing the heavy lifting, so you can focus on the science with reduced risk, shortened project timelines and improved outcomes. So get in touch at operations@axolbio.com and let us know- what can we do to help? #iPSCs #StemCells #DrugDiscovery #biotech #biopharma

From the lab to the bench, scaling up regulatory #Tcelltherapy #RegulatoryTcells (#Tregs) are crucial for maintaining #immunebalance and preventing overactive #immuneresponses. While their therapeutic use is a rapidly expanding field of research, producing Tregs presents significant challenges, including contamination risks and human error. Next week, Thermo Fisher Scientific’s Hany Meås and the University of British Columbia’s Megan K. Levings will discuss the growing potential of Treg #celltherapy for treating #autoimmuneconditions, and the considerations for producing these therapeutics in a closed, automated environment. Register for this #webinar below:

From the lab to the bench, scaling up regulatory #Tcelltherapy #RegulatoryTcells (#Tregs) are crucial for maintaining #immunebalance and preventing overactive #immuneresponses. While their therapeutic use is a rapidly expanding field of research, producing Tregs presents significant challenges, including contamination risks and human error. Next month, Thermo Fisher Scientific’s Hany Meås and the University of British Columbia’s Megan K. Levings will discuss the growing potential of Treg #celltherapy for treating #autoimmuneconditions, and the considerations for producing these therapeutics in a closed, automated environment. Register for this #webinar below:

Reasons to come by booth 630 and meet the Sannova Analytical team? 1.) We’ll be discussing the difference that pairing excellent science with a boutique project delivery approach can make for your studies. — Your program receives our complete attention, and we help our customers solve their most difficult problems in bioanalysis. 2.) We schedule projects in our lab one week after our customers give us the green light! — No waiting on team assignment, and we act as an integrated extension of your team. The complexities of developing #advancedtherapies are tough enough to navigate, don’t add an overly complex CRO to the mix, choose #SannovaAnalytical!

Our continued pledge to make iPSCs models simpler, more accessible and cheaper to run. Here at Axol, we see the momentum behind greater use of iPSC-derived models build and build and build. No longer an esoteric toe-in-the-water, we see major neuroscience groups within academic and biopharma sites heavily investing time, effort and funds into the utility of these 'more human' models. We recognize our responsibility to drive forward greater functionality, standardization and characterization of the cells that fuel the models. We have also pledged to make drive down costs, make protocols simpler and build new levels of quality systems throughout manufacturing and support. So if it's quicker, cheaper, better models of human disease you're looking for, get in touch to see how we can help at operations@axolbio.com Axol, the first choice for iPSC-derived cells. #iPSCs #StemCells #DrugDiscovery #biotech

Our continued pledge to make iPSCs models simpler, more accessible and cheaper to run. Here at Axol, we see the momentum behind greater use of iPSC-derived models build and build and build. No longer an esoteric toe-in-the-water, we see major neuroscience groups within academic and biopharma sites heavily investing time, effort and funds into the utility of these 'more human' models. We recognize our responsibility to drive forward greater functionality, standardization and characterization of the cells that fuel the models. We have also pledged to make drive down costs, make protocols simpler and build new levels of quality systems throughout manufacturing and support. So if it's quicker, cheaper, better models of human disease you're looking for, get in touch to see how we can help at operations@axolbio.com Axol, the first choice for iPSC-derived cells. #iPSCs #StemCells #DrugDiscovery #biotech

Missed SLAS earlier this month? Make sure to download our poster! From the 3rd to 7th February, we were in Boston for the Society for Laboratory Automation and Screening (SLAS) International Conference, discussing our work with human iPSC technology for research and drug discovery. Alongside discussions on quality iPSC manufacturing, functional QC and in vitro models, we presented a poster titled "Differentiation of multiple iPSC lines to different cell types to enable cohort analysis in neurodegeneration: challenges and learnings". Listen to our Project Manager, Sian Humphreys presenting the key findings in the poster: https://hubs.la/Q02m2bc70 Click here to download the poster: https://hubs.la/Q02m24Zy0 #iPSCs #SLAS #biotech #StemCells #DrugDiscovery

When it comes to iPSCs, in 2024 we're asking one simple question: what can we do to help? We believe in the enormous potential of iPSCs for drug discovery to unlock better, safer therapies for neurodegenerative and cardiovascular diseases. And we're here to support drug discovery researchers who want to harness iPSC technology and realize this potential. We've been working with iPSCs in a quality-focused environment for over a decade and have developed a deep understanding of the challenges of this space. So whether it's compound screening on physiologically useful models, iPSC creation, QC and banking, or the large-scale supply of functionally-relevant cells, we can help you. Our capabilities include: • High-quality, functionally consistent axoCells™ • A bank of over 70 fully characterized and licensed axoLines™ • Our QC-rich axoServices™ • The ability to work with you to build, validate and use iPSC-based axoModels™. Collaboration is one of our six core company values; we're here to help you by doing the heavy lifting, so you can focus on the science with reduced risk, shortened project timelines and improved outcomes. So get in touch at operations@axolbio.com and let us know- what can we do to help? #iPSCs #StemCells #DrugDiscovery #biotech #biopharma